TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01600976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.
Study: NCT01849497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab Pre-filled Syringe
Description: Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab AI/pen
Description: Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
Study: NCT02843763

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample (28 ml)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample (28 ml)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample (28 ml)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample (28 ml)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample (28 ml)
Study: NCT02560363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 immediate release (IR) oral suspension
Description: 120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 immediate release (IR) oral suspension
Description: 120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 immediate release (IR) oral suspension
Description: 120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 immediate release (IR) oral suspension
Description: 120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [fast]
Description: 120 mg (2 x 60mg capsules) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [fast]
Description: 120 mg (2 x 60mg capsules) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [fast]
Description: 120 mg (2 x 60mg capsules) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [fast]
Description: 120 mg (2 x 60mg capsules) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [intermediate]
Description: 120 mg (2 x 60mg capsules) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [intermediate]
Description: 120 mg (2 x 60mg capsules) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [intermediate]
Description: 120 mg (2 x 60mg capsules) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [intermediate]
Description: 120 mg (2 x 60mg capsules) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [slow]
Description: 120 mg (2 x 60mg capsules) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [slow]
Description: 120 mg (2 x 60mg capsules) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [slow]
Description: 120 mg (2 x 60mg capsules) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [slow]
Description: 120 mg (2 x 60mg capsules) single dose
Study: NCT02897232

Intervention type: OTHER
Intervention: Survey
Description: Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination

Intervention type: OTHER
Intervention: Survey
Description: Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
Study: NCT03948633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-faceted knowledge translation intervention
Description: The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
Study: NCT01549626

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Defatted flaxseed flour
Description: 30g defatted flaxseed flour per day for breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Defatted flaxseed flour
Description: 30g defatted flaxseed flour per day for breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Golden flaxseed flour
Description: 30 grams of golden flaxseed flour per day for breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Golden flaxseed flour
Description: 30 grams of golden flaxseed flour per day for breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole brown flaxseed flour
Description: 30 grams of whole brown flaxseed flour per day for breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole brown flaxseed flour
Description: 30 grams of whole brown flaxseed flour per day for breakfast
Study: NCT00354081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)
Description: folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid, vitamin B12 (cyanocobalamin)
Description: folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin B6 (pyridoxine)
Description: vitamin B6 40 mg, in a capsule, taken orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, in a capsule, taken orally once a day
Study: NCT02884154

Intervention type: DEVICE
Group type: OTHER
Intervention: Echotip ProCoreⓇ HD Ultrasound Biopsy Needle
Study: NCT00302510

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: immunoadsorption
Description: immunoadsorption
Study: NCT02955420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC 007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 0.9 %
Study: NCT00590044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine+ glulisine
Description: Daily insulin glargine + glulisine before meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH + Regular insulin
Description: Split-mixed NPH + Regular insulin twice daily
Study: NCT01329887

Intervention type: DRUG
Group type: OTHER
Intervention: ketanserin
Description: ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
Study: NCT03521830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 480mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg IV every 4 weeks for 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: 480 mg IV q4wks
Study: NCT01937572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visionaire system (Knee MRI)

Intervention type: OTHER
Group type: OTHER
Intervention: No Knee MRI
Study: NCT02437617

Intervention type: PROCEDURE
Intervention: Tumor Tissue
Description: Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.

Intervention type: PROCEDURE
Intervention: Tumor Tissue
Description: Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
Study: NCT02901574

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal or Cathodal tDCS
Description: 2 mA or Anodal or Cathodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge (anode in group anode or cathode in group cathode) is placed on the right cerebellum. The stimulation will be delivered at an intensity of 2 mA in a ramp-like fashion for a maximum of 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 2 mA of Anodal tDCS or Cathodal tDCS is induced between two 5cm X 5cn saline soaked sponges where one sponge (anode in group Anode and cathode in group Cathode) is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computerized naming therapy
Description: Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized naming therapy
Description: Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
Study: NCT03581279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T2Lyme Panel testing
Description: The T2Lyme Panel is an investigational use in vitro diagnostic (IVD) designed to qualitatively detect and identify the major causative agents of Lyme disease (Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, as well as an inclusive Borrelia spp. detection channel) from K2EDTA human whole blood samples.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T2Lyme Panel testing
Description: The T2Lyme Panel is an investigational use in vitro diagnostic (IVD) designed to qualitatively detect and identify the major causative agents of Lyme disease (Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, as well as an inclusive Borrelia spp. detection channel) from K2EDTA human whole blood samples.
Study: NCT03160443

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ambulatory cares in a day-hospital (University Hospital of Montpellier) specialized in the evaluation of eating disorders
Description: All patients assessed in the day-hospital will performed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensitometry~* Psychiatric assessment~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)
Study: NCT02844621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20mg orally once daily
Study: NCT01475929

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic supplement
Description: A single strain probiotic supplement given at two doses

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplement
Description: A single strain probiotic supplement given at two doses

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplement
Description: A single strain probiotic supplement given at two doses
Study: NCT01514136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ostomy appliance: convex 1-piece drainable
Description: 8 variations of an ostomy devices are tested
Study: NCT04236895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gan & Lee Insulin Glargine Injection
Description: All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gan & Lee Insulin Glargine Injection
Description: All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gan & Lee Insulin Glargine Injection
Description: All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.
Study: NCT01648894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery after 11 weeks of delay after chemoradiotherapy.
Description: Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 11 weeks of delay after the end of chemoradiotherapy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery after 7 weeks of delay after chemoradiotherapy
Description: Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 7 weeks of delay after the end of chemoradiotherapy
Study: NCT00445523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax® (Immunological Vaccine Therapy)
Description: 16 Intramuscular injections of TroVax® over 47 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax® (Immunological Vaccine Therapy)
Description: 16 Intramuscular injections of TroVax® over 47 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Description: 36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)
Study: NCT01561495

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Study: NCT02780050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core muscle activation using physical fitness
Description: 2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 1st and 2nd chest compression.
Study: NCT01827579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD25/71 allodepleted donor T-cells
Description: CD25/71 allodepleted donor T-cells will be administered at a dose of 10\^5 /kg at day 30 post-SCT, 3 x 10\^5 /kg at day 60 and 10\^6 /kg at day 90 post transplant
Study: NCT02374398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: see arm/group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: see arm/group descriptions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquamantys System
Description: see arm/group descriptions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquamantys System
Description: see arm/group descriptions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard Electro-cautery and Saline
Study: NCT03914404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: γ-linoleic acid and placebo(Thioctic Acid)
Description: * γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~* Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioctic Acid and placebo(γ-linoleic acid)
Description: * Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~* γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time.
Study: NCT02180620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No exercise
Description: During the no exercise trial (NoEX), the participants will remain sedentary during testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal then exercise
Description: During the post-meal exercise trial (M→EX), 45 min of resistance training will be performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise then meal
Description: During the exercise prior to the meal trial (EX→M), 45 min of resistance training will be performed
Study: NCT02277977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound
Description: Contrat enhanced ultrasound during septic shock
Study: NCT00247741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal administration of articaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal administration of lidocaine
Study: NCT05558306

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery of distal radius fracture
Description: Surgery of distal radius fracture for displaced fractures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reduction and cast treatment of distal radius fracture
Description: Reduction and cast treatment of distal radius fracture for minimally displaced fractures
Study: NCT02146599

Intervention type: OTHER
Intervention: Administration of patient self-assessment
Study: NCT02371122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapy Setting 1 (Medtronic)
Description: RestoreSensor or RestoreUltra Setting 1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapy Setting 2 (Medtronic)
Description: Medtronic RestoreSensor or RestoreUltra Setting 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapy Setting 3 (Medtronic)
Description: Medtronic RestoreSensor or RestoreUltra Setting 3

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapy Setting 4 (Medtronic)
Description: Medtronic RestoreSensor or RestoreUltra Setting 4
Study: NCT01748942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00637975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone
Description: Arm A - 20 mg/day~Arm B - increasing dose startnig at 20 mg/day~For 15 days or until unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: Arm A - 20 mg/day~Arm B - increasing dose startnig at 20 mg/day~For 15 days or until unacceptable toxicity develops.
Study: NCT01748942

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery
Description: Undergo TORS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoral Robotic Surgery
Description: Undergo TORS
Study: NCT04401748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous (SC) or Intravenous (IV) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Subcutaneous (SC) or Intravenous (IV) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablet; Oral
Study: NCT00255762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01236664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory training
Description: The Memory at Work program is a 4-hour classroom-based workshop that is led by a professional trainer. The format of the program is experiential, with a heavy focus on discussion, self-discovery, and hands-on use of trained skills. Specific memory compensation techniques are trained. Training consists of an explanation of each technique (i.e., how and when to use it, the science behind the technique) and ample opportunities for hands-on use of the strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Workshop
Description: The control workshop consists of a 4-hour program that will train techniques for successfully completing Sudoku, word, and logic puzzles. Like the experimental intervention, the control workshop will be engaging and challenging, and will involve a combination of individual and group activities.